Pierre Fabre Laboratories’ Post

Incredible scientists, physicians and experts in clinical research. Great teams collaborating and enhancing the knowledge in oncology. #ESMO2024 #Oncology #ClinicalTrials #CancerResearch #Innovation #MedicalAdvances #Collaboration #ClinicalTrials #ClinicalResearch

What makes Europe a prime hub for #oncology trials? José Luis García, MD, Ph.D., Senior Medical Strategy Director at the IQVIA Oncology Center of Excellence, explains how established networks and robust national health systems position #Europe as a leader in oncology research. See his insights from the 2024 Pre-ESMO Symposium and discover the opportunities for advancing cancer care across the region. Watch the on-demand session: https://bit.ly/3VmBs73.

https://conta.cc/3XVvjir This week’s feature commentaries include: 1. AbbVie’s c-MET-targeted ADC Teliso-V might beat the army of TROP-2 ADCs to gain the FDA approval before them, thanks to a biomarker-selected approach. Our editor Jiamin Zhuo has more for the story. 2. China-originated innovations are the common theme among Kailera Therapeutics’ impressive launch, Roche’s new breast cancer strategy, and CARVYKTI’s impressive overall survival data. Is China-originated innovation becoming a necessity to stay competitive in some fields? Our editor Leon Tang has more.

If you are found to have a potentially lethal malignancy, you will need #MolecularTesting to ascertain likely best #therapy. Here is how.

➖ QUARTERLY REPORT ➖   #Amplia has today released its Quarterly Activities and Cash Flow Report for the quarter ended 30 June 2024.    Key highlights for the quarter include:   ✔ Updated data and analysis from the Phase 1b ACCENT trial in pancreatic cancer presented at the prestigious annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) ✔ Recruitment in the ACCENT Phase 2a trial has progressed well and in early June we reported 24 of 26 patients had been recruited.  ✔ The inaugural meeting of the Company’s Clinical Advisory Board was held.   Read today’s ASX release here 👉 https://lnkd.in/gtiCG5QN   $ATX #ASX #research #innovation #cancerresearch #pancreaticcancer #clinicaltrial

Last year, CCF team members Stacie Lindsey and Melinda Bachini along with colleagues in the field Rachna Shroff, MD, FASCO and Wendy Selig, authored the #whitepaper "Cross-over arms in oncology clinical trials: An important consideration for patients," highlighting a revolutionary approach to designing cancer clinical trials. The paper emphasizes the importance of patient-centric trial designs and introduces the concept of "cross-over" options, opening new doors for patients with limited treatment options. It also encourages sponsors, investigators, and regulators to advance patient-centric trial designs. This initiative is crucial for our CCF community as it represents a significant step forward in #cholangiocarcinoma cancer research and patient care. Read more about the whitepaper here: https://lnkd.in/eRJ_TY3h. #CCAhope #cureCCA #bileductcancer #ClinicalTrials #NationalCancerResearchMonth #PatientPoweredResearch See less

Here’s the latest from Curious Dr. George! Read “Protean BioDiagnostics: One Way to Access Full-Service Precision Oncology Testing” here: bit.ly/CCCDGProteanBioDx The use of advanced molecular testing of various cancers over the last 10-15 years has driven development of the field of precision oncology. Now, many patients with a variety of cancer types can benefit from targeted therapies. However, accessing precision testing and treatment can be a major challenge. Our Curious Dr. George Lundberg, MD, asks Anthony Magliocco MD, Founder and CEO of Protean BioDiagnostics, how his company enables better access. #CuriousDrGeorge #CancerResearch #MolecularTesting #MolecularDiagnostics #PersonalizedOncology #PrecisionMedicine #TargetedTherapy

🎧 Episode 8 of the 'LARVOL CLIN - Building In Public' Podcast is now live! Join Bruno Larvol and Kalpana Devi, Director at LARVOL, as they discuss the importance of the Landscape feature in LARVOL CLIN. This function compares main treatments with clinical trial data, offering valuable insights that serve as a guideline in oncology. It provides a comprehensive data table and the emerging data landscape for cancer patients. Tune in now: https://bit.ly/3V2Mwpr With LARVOL CLIN, stay informed and ahead in the fast-evolving world of oncology. Access key insights, stay updated on new developments, and leverage data intelligence to elevate your practice. Discover more: https://bit.ly/4da5h1k #LARVOL #Oncology #CancerResearch #MedicalOncology #CancerTreatment #OncologyUpdates #MedicalPodcast #LARVOLCLIN

🌐 Discover the Top 10 Oncology CME Conferences in the USA - https://bit.ly/3B4eUk7 🎗️ Cancer is the second leading cause of death in the United States, highlighting the critical need for ongoing education and advancements in oncology. As treatment landscapes evolve, healthcare professionals must stay informed about the latest research and clinical practices. 📊 Attending oncology CME conferences is a valuable opportunity to gain cutting-edge knowledge, network with experts, and enhance your clinical skills. 🩺 This blog highlights the Top 10 Oncology CME Conferences in the USA that provide exceptional learning experiences and insights into pressing oncology issues. #USA #Florida #Oncology #MedicalEducation #CancerCare #HealthcareProfessionals #OncologyConferences #eMedEvents

⏳🇺🇸 3 days until #ASCO2024! 🚀 Next Friday, the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago will start. On June 1, between 9:00 and 12:00, XENOTHERA will present the first data from the XON7 FIPO trial, abstract 2673. Professor Jaafar Bennouna from Hopital Foch (Suresnes, France) and Dr. Françoise Shneiker, Medical Director at XENOTHERA, will share the initial clinical data on XON7, our innovative glyco-humanized polyclonal antibody showing promise for patients with refractory solid tumors. We look forward to discussing our innovative research and its potential impact on cancer treatment. #XON7 #ClinicalTrial #Solidtumors #Oncology #Innovation #PatientCare #CancerResearch